News from sierra oncology A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 27, 2019, 07:00 ET Sierra Oncology Launches Campaign Exploring Non-Dilutive Strategic Options to Support Development of its DDR Assets

- Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Exploring non-dilutive options to support future...


Jun 05, 2019, 06:00 ET Sierra Announces Momelotinib Granted FDA Fast Track Designation

- Fast Track designation highlights the potential for momelotinib to address the significant unmet needs of patients with Intermediate/High-Risk...


Jun 04, 2019, 17:04 ET Sierra Announces FDA Regulatory Clarity for Momelotinib & Design of the MOMENTUM Phase 3 Clinical Trial

- MOMENTUM Phase 3 clinical trial planned for launch in Q4 2019; topline efficacy data anticipated in Q4 2021 – - World renowned myelofibrosis expert ...


Jun 03, 2019, 07:00 ET Sierra Holds Analyst & Investor Event for SRA737

- Sierra management and distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit discuss clinical findings and possible next...


Jun 01, 2019, 09:00 ET Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration

- Sierra reports 30% response rate for SRA737+LDG in anogenital cancer - - Anti-cancer activity demonstrated across multiple indications and genetic...


May 28, 2019, 07:00 ET Sierra Oncology to Present Momelotinib and SRA737 Overview at the Jefferies Global Healthcare Conference in New York

- Presentation scheduled for 8:00 am ET on June 5, 2019 - VANCOUVER, May 28, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug...


May 15, 2019, 17:00 ET Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1st - - Sierra to hold Analyst...


May 08, 2019, 07:00 ET Sierra Oncology Reports First Quarter 2019 Results

Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual...


May 06, 2019, 07:00 ET Sierra Oncology to Attend Two Investor Conferences in May

VANCOUVER, May 6, 2019 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted...


Apr 03, 2019, 08:00 ET Sierra Reports Late-Breaking SRA141 Preclinical Data in Poster at AACR 2019

- Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action - VANCOUVER, April 3,...


Apr 01, 2019, 16:05 ET Sierra Reports Late-Breaking Preclinical Data for SRA737 Presented at AACR 2019

- Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus...


Mar 05, 2019, 07:00 ET Sierra Oncology to Present at the Cowen 39th Annual Health Care Conference in Boston

- Dr. Christian Hassig, CSO, scheduled to present at 10:00 a.m. ET on March 13, 2019 - VANCOUVER, March 5, 2019 /PRNewswire/ - Sierra Oncology, Inc....


Feb 28, 2019, 07:00 ET Sierra Oncology Reports 2018 Year End Results

- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 preliminary data anticipated in H1 2019 - VANCOUVER, Feb. 28, 2019...


Feb 27, 2019, 16:30 ET Sierra Oncology Announces Late-Breaking Oral and Poster Presentations at AACR 2019 for SRA737 and SRA141 Preclinical Data

- Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1...


Jan 23, 2019, 07:00 ET Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit

- "Addressing Intrinsic & Acquired PARP Inhibitor Resistance Through Chk1 Inhibition" scheduled for 9:00 am ET on January 30 in Boston - VANCOUVER,...


Dec 03, 2018, 07:00 ET Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib

- 44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion ...


Nov 29, 2018, 17:00 ET Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737

- SRA737 synergizes with immune checkpoint blockade in small cell lung cancer (SCLC) – - Activates immune signaling STING pathway - - Data reported...


Nov 27, 2018, 17:00 ET Sierra Oncology to Host Analyst Call Highlighting Clinical Data on Momelotinib's Anemia Benefit

- Call to include Dr. Srdan Verstovsek and will discuss emerging clinical data demonstrating momelotinib's unique anemia benefit in patients with...


Nov 15, 2018, 05:00 ET Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium

- SRA737 demonstrates preclinical efficacy in aggressive CCNE1-amplified and MYCN‑overexpressing high-grade serous ovarian cancer patient-derived...


Nov 13, 2018, 07:00 ET Sierra Oncology Reports SRA141 Preclinical Efficacy at EORTC-NCI-AACR Symposium

- Novel oral Cdc7 inhibitor, SRA141, demonstrates competitive target selectivity and robust efficacy in several cancer models - VANCOUVER, Nov. 13,...


Nov 08, 2018, 07:00 ET Sierra Oncology Reports Third Quarter Results

- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 Monotherapy and LDG Combination trial preliminary data anticipated in H1...


Nov 07, 2018, 07:00 ET Sierra Oncology to Present at the Jefferies 2018 London Healthcare Conference

- "Targeted Therapeutics for Hematology & Oncology" scheduled for 5:20 p.m. GMT on November 14, 2018 - VANCOUVER, Nov. 7, 2018 /PRNewswire/ - Sierra...


Nov 01, 2018, 09:20 ET Sierra Oncology to Report Clinical Data at ASH 2018 from Translational Biology Study of Momelotinib in Transfusion Dependent Patients

– Biomarker data obtained from 41 transfusion dependent patients support ACVR1 mechanism of action for momelotinib's anemia benefit in myelofibrosis...


Oct 04, 2018, 07:00 ET Sierra Oncology to Host KOL Call with Dr. Srdan Verstovsek Presenting "Unmet Medical Needs in Myelofibrosis"

VANCOUVER, Oct. 4, 2018 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted...


Aug 22, 2018, 07:05 ET Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib

- Up to $15 million available in three $5 million tranches; additional $25 million potentially available - VANCOUVER, Aug. 22, 2018 /PRNewswire/ -...